Chris Tucker
Analyst · CJS Securities. Your line is open
Thanks, Vic. As we have done in the last few quarters, we’re going to use a chart presentation to walk through the financial results. Starting on Chart 3, we have the overall financial highlights for the fourth quarter. As Vic mentioned, we had a great quarter, and this chart illustrates that very well. Sales were up nearly 25%. Adjusted EBIT was up over 50% and adjusted EPS was up over 42%, a great growth quarter for ESCO. The chart does show orders down approximately 5%. That is a function of last year’s fourth quarter acquisition of Altanova and Phoenix. The acquired backlog came through as orders last year, so it makes for a pretty tough comparison. Overall, the order trends have remained robust and our record year-end backlog of $695 million demonstrates the strength of the business. The last thing I wanted to highlight on this chart was organic sales growth of 19%. Two of the three business platforms grew at over 20% organically to drive this very strong finish to 2022. Next, on Chart 4, we’ll get into segment results, starting with A&D. A great finish to the year here as well with nearly 30% sales growth and EBIT margins up over 4 points. Commercial aerospace recovery led to sales growth as we saw sales increase by 50% in this market. This was led by our PTI and Mayday subsidiaries. Beyond that, we still saw explosive growth from other parts of the business with Defense Aerospace, Navy and Space, all up more than 20%. The teams here have been managing a number of supplier and labor challenges. So it was great to see them work through those issues and deliver this quarter. On the next chart, we have the Utility Solutions Group, where we also had very strong sales performance. Organic sales growth was 21% overall with high levels of activity from electric utility customer base and the renewables business. EBIT margins were down 0.6 point as we did see some unfavorable mix here, but EBIT dollars were up 33%. The acquisition impact was favorable in the quarter with Altanova and Phoenix adding 16 points of growth. Going forward, these businesses will be folded into the base company, but we are very excited about the progress made with both acquisitions during the first year as part of ESCO. The last segment to talk about is test, a good finish to the year for this group, with sales up 8% and EBIT margins up 1.7 points, really nice margin expansion here as we saw solid leverage on the volume increase, and we also saw good impacts from pricing actions. Orders did drop for Test during the quarter. Last year in Q4, we saw significant orders in the Power filter product line, so that is the main driver of the decrease. We still have a 19% increase in backlog compared to prior year-end. So the business had some nice runway as we move into ‘23. Next on Chart 7. I’ll take a snapshot of the full year results. As you saw in the press release, it was a record year for ESCO on many fronts. The sales performance was strong with a 20% increase driven by 13% organic and 7% from recent acquisitions. Adjusted EBIT margins expanded 0.8 points and adjusted EPS was up 24% as we saw favorable impacts from volume leverage, price and cost reductions, which more than offset the inflationary impacts of material and labor. Orders were up over 20%, resulting in $695 million year in backlog with good growth from all three segments. Chart 8 has the cash flow highlights. Operating cash flow increased to $135 million, a great result as we had lagged on cash flow through the first three quarters. Capital spending was up just over $5 million and acquisition spending dropped significantly with 2021, including ATM, Altanova, and Phoenix, while 2022 included only the NEco acquisition. We did restart a share repurchase program in 2022, and we’re able to buy back $20 million worth of stock during the year. Chart 9 has full year highlights for each of the segments. I’m not going to read through every number here. Obviously, for us, this is a really good-looking chart with lots of arrows pointing in the up direction, double-digit increases of sales and EBIT for all THREE business segments. So 2022 was really a good year of recovery for both A&D and USG after the pandemic had negatively impacted those businesses in ‘20 and ‘21. And then for Test, we really had continued growth after good performance throughout the pandemic period. The last chart will be our guidance for 2023. We are expecting another year of growth in ‘23 with sales growth of 6% to 8% and adjusted EBIT dollar growth of 10% to 15%. In the press release, we detailed the growth expectations by segment. We expect A&D to lead the sales growth with low double-digit growth, followed by USG with mid-single-digit growth and Test expecting low single-digit growth. From an EPS perspective, we are planning for growth in the range of 8% to 12%, slightly lower than the EBIT growth as we expect increases in interest expense given the current interest rate environment. Overall, you’re looking at another year of nice growth after the great year we had in 2022. That concludes the financial update, and now I’ll turn it back over to Vic.